Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure (LAICA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00988806|
Recruitment Status : Unknown
Verified September 2013 by Martín J García González, Hospital Universitario de Canarias.
Recruitment status was: Enrolling by invitation
First Posted : October 2, 2009
Last Update Posted : September 18, 2013
Hospital Universitario de Canarias
Information provided by (Responsible Party):
Martín J García González, Hospital Universitario de Canarias
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||December 2014|
García-González MJ, de Mora-Martín M, López-Fernández S, López-Díaz J, Martínez-Sellés M, Romero-García J, Cordero M, Lara-Padrón A, Marrero-Rodríguez F, del Mar García-Saiz M, Aldea-Perona A; LAICA study investigators. Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study. Cardiovasc Drugs Ther. 2013 Dec;27(6):573-9. doi: 10.1007/s10557-013-6476-7.